No company matches — see all tickers
Officers expect to reaffirm FY2026 earnings and benefit expense ratio outlook in investor meetings; adjusted EPS excludes net unfavorable items.
Medical costs outpaced insurance pricing, squeezing margins despite CarelonRx specialty-pharmacy growth.
Government medical costs squeezed margins despite improved Individual ACA performance; management raised FY2026 guidance.
Coverage: 10-K, 10-Q and 8-K filings filed since Jul 1, 2026.
Request longer coverage
Company data: Wikidata Q677488
We read every message.
